

Second Supplemental Amendment
U.S.S.N. 09/292,217
Page 3 of 4

REMARKS

Applicant amends claims 1 and 20. Accordingly, after entry of this Supplemental Amendment, claims 1, 2, 4-9, 12-24, 27 and 31- 37 will be pending for examination.

Independent claims 1 and 20 are amended to further clarify the claimed invention. Specifically, independent claims 1 and 20 are amended to recite a target antigen associated with cancer and expressed on a target cell in a solid tumor.


Support for these amendments can be found in the specification as filed, *inter alia*, on page 13, line 12 through page 14, line 4; page 15, lines 3-16; and in the Examples.

Applicant submits that no new matter is introduced by these amendments.

CONCLUSION

Applicant submits that on the basis of the foregoing remarks and claim amendments, claims 1, 2, 4-9, 12-24, 27, and 31-37 are in condition for immediate allowance. Accordingly, Applicant respectfully requests entry as such. The Examiner is respectfully requested to call the undersigned at (617) 248-7240 prior to issuing a further Office action in this application, if necessary.

Respectfully submitted,



Patrick R.H. Waller, Ph.D.
Attorney for the Applicant
Reg. No. 41, 418

Date: November 1, 2002
Testa, Hurwitz & Thibault
125 High Street
Boston, MA 02110
(617) 248-7240

2524138_1

Second Supplemental Amendment
U.S.S.N. 09/292,217
Page 4 of 4

MARKED-UP VERSION OF AMENDED CLAIMS SHOWING AMENDMENTS

1. (Four Times Amended) A method of inducing a cytotoxic immune response against a solid tumor in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen associated with cancer and expressed on a target cell in a solid tumor and interleukin 2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.

20. (Four Times Amended) A composition for inducing an immune response against a solid tumor in a mammal, the composition comprising in combination:

(i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen associated with cancer and expressed on a target cell in a solid tumor and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.